Innovations in Blood Cancer Treatment: Navigating CAR T-cell and Bispecific Therapies (Participant)

Credit Available: AANP, ASWB, CABRN

 

Enroll in this Course

FREE

access until October 31, 2026 12:00 am

 

Enroll Now

Activity Description

This recorded webinar is derived from ONS Congress 2025. Earn free CE credit, as you deepen your expertise on the availability and application of CAR T-cell and bispecific therapies to treat patients with hematologic malignancies. Learn about treatment protocols and procedures, identifying and managing common adverse events, and management of bispecific therapy in the community.

Broaden your understanding of the newest treatments, safety and efficacy, patient management, disparities in care, resources for patient education and support from The Leukemia & Lymphoma Society, and more in this interactive session, to improve patient care!

Time to Complete Activity: 1.5 hours

This course is available from:

June 3, 2025 until October 31, 2026

Course Instructors

Tara M. Graff, DO, MS Speaker

Medical Oncologist, Director of Clinical Trials, Mission Cancer and Blood/UIHSMG, Director of Cellular Therapy, ONCare Alliance, Des Moines, IA

Jonathan Gutman, MD Speaker

Director of Cellular Therapies, Professor, Medicine-Hematology, University of Colorado, Aurora, CO

Michelle McDaniel, RN, CIONS President Speaker

Mission Cancer, Des Moines, IA

Samantha Schad, MSN, RN, OCN, WTA-C Speaker

Oncology Clinical Practice Leader, Hospital of the University of Pennsylvania, Philadelphia, PA

Target Audience

Oncology nurses and nurse practitioners involved in the care of patients with hematologic malignancies.

Educational Objectives
After completing this activity, the participant should be better able to:

• • Describe the principles and mechanisms of CAR T- cell and bispecific therapies in treating blood cancers
  • Identify clinical indications, including recent FDA approvals and therapies in clinical trials, and disparities in care
  • Explain treatment protocols, including pre-treatment conditioning, infusion procedures, identifying and managing common adverse events, management of bispecific therapy in the community, and strategies to improve patient-centered care
  • Assess the efficacy of CAR T-cell and bispecific therapies to make informed decisions about treatment options
  • List resources and education to support patients, caregivers, and healthcare professionals

Accreditation, Support and Credit

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to XX contact hours of accredited education.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (ONC, CBCN, CPHON, AOCNP), Oncology Nursing Practice (ONC), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Symptom Management, Palliative Care, Supportive Care (ONC, CPHON, AOCNP), Treatment (OCN, CBCN, AOCNP, CPHON). Total points: 1.5*
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Support Statement

This activity is supported by Autolus Therapeutics.

Providers

This activity is provided by The Leukemia & Lymphoma Society.

Disclosure of Conflicts of Interest Policy

All persons who may impact the content of a CE activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months. The participants in this CE activity must be made aware of any such financial relationship(s). This disclosure policy is intended to protect all parties involved from any potential conflict of interest that may arise

Faculty Disclosures

Tara M. Graff, DO, MS, has financial relationships with the following:
Advisory Board: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, BMS, Genmab, Incyte, Lilly
Consultant: AbbVie, ADC Therapeutics, AstraZeneca, Beigene, BMS, Genentech, Genmab, Gilead/Kite, Janssen, Pfizer
Steering Committee: AbbVie, Genmab
Speaker: AbbVie, BeiGene, Genmab

Jonathan Gutman, MD, does not have any financial relationships with ineligible companies.

Michelle McDaniel, RN, CIONS President, does not have any financial relationships with ineligible companies.

Samantha Schad, MSN, RN, OCN, WTA-C, does not have any financial relationships with ineligible companies.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners just participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated.

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.